AIM — AIM ImmunoTech Share News
0.000.00%
Last trade - 00:00- $8.65m
- $6.99m
- $0.09m
Brief: Aim Immunotech Receives Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligen® For The Treatment Of Locally Advanced Pancreatic Cancer
Brief: Aim Immunotech Announces That The First Subject Is Enrolled In The Phase 1B/2 Study Evaluating Ampligen® In Combination With Astrazeneca’S Imfinzi® For The Treatment Of Late-Stage Pancreatic Cancer
Brief: Aim Immunotech Announces Open Enrollment For Phase 1B/2 Study Evaluating Ampligen (Rintatolimod) In Combination With Astrazeneca’S Imfinzi (Durvalumab) For The Treatment Of Pancreatic Cancer
Brief: Aim Immunotech Completes Treatment Of Last Subject In Phase 2 Study Evaluating Ampligen® For The Treatment Of Post-Covid Conditions
Brief: Kellner Group Urges AIM Immunotech Stockholders To Vote On Gold Proxy Card Today
Brief: AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer
Brief: AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
Brief: AIM ImmunoTech Engages Azenova For Ampligen Pipeline Programs
U.S. RESEARCH ROUNDUP- Amgen, FedEx, Zscaler
To Proceed With Aim Director Nominations And Proxy Solicitation
Brief: Aim Immunotech Inc Rejects Director Nomination Notice From Activist Group
Brief: Aim Immunotech Enrolls And Doses First Subject In Phase 2 Study Evaluating Ampligen® For The Treatment Of Post-Covid Conditions
Brief: AIM Immunotech Announces Authorizations To Begin A Phase 1B/2 Study For The Treatment Of Pancreatic Cancer
Brief: Aim Immunotech And Japanese National Institute Of Infectious Disease Enters Into A Material Transfer And Research Agreement
U.S. RESEARCH ROUNDUP-Empire State, Integra Lifesciences, Lowe's Companies
U.S. RESEARCH ROUNDUP-Amyris, APi Group, Rambus
Brief: AIM Immunotech Reports First Quarter Financial Results And Provides Pipeline Update
Brief: Aim Immunotech Inc Entered Into An Equity Distribution Agreement With Maxim Group Llc
Brief: Aim Immunotech Appoints W. Neal Burnett As Chairman Of Scientific Advisory Board